Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing


CEO Kleanthis Xanthopoulos touts the San Diego biotech’s engineering prowess in developing iPSC-derived NK cells and macrophages against cancer

Shoreline Biosciences has developed induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells and macrophages that are optimized by applying gene editing to target specific genes with properties sought by the company. San Diego-based Shoreline says its “intelligently engineered” NK cells can target and kill tumors more effectively and efficiently…

[Full article text:

Recommended Posts